Adam Brufsky
Overview
Explore the profile of Adam Brufsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
153
Citations
4261
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Lv W, Brufsky A, Ochiya T
Front Hum Neurosci
. 2025 Feb;
19:1554890.
PMID: 39916730
No abstract available.
3.
Rajendran S, Petruzzi M, Ren D, Bender C, Brufsky A, Rosenzweig M
Future Oncol
. 2025 Jan;
21(5):565-568.
PMID: 39865560
Background: The accessibility and outcomes of cyclin-dependent kinase 4 and 6 inhibitors (CDKi) in metastatic breast cancer (MBC) according to demographic factors are unknown. Research Design And Methods: Retrospective review...
4.
Chang A, Balic M, Bartholow T, Bhargava R, Brown D, Brown L, et al.
bioRxiv
. 2024 Nov;
PMID: 39574596
Breast cancer affects 1/8 of women throughout their lifetimes, with 90% of cancer deaths being caused by metastasis. However, metastasis poses unique challenges to research, as complex changes in the...
5.
Brufsky A, Liu X, Li B, McRoy L, Chen C, Makari D, et al.
Oncologist
. 2024 Oct;
29(12):1032-1043.
PMID: 39418346
Background: Patients with cardiovascular disease (CVD) comorbidities are often excluded from participating in breast cancer clinical trials. Consequently, data to inform treatment decisions for patients with hormone receptor-positive/human epidermal growth...
6.
Brufsky A, Kwan M, Sandin R, Stergiopoulos S, Karanth S, Cha-Silva A, et al.
Breast Cancer Res Treat
. 2024 Aug;
208(2):223-235.
PMID: 39177933
Purpose: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have improved patient survival in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) in clinical trials and real-world studies. However,...
7.
Kepp K, Aavitsland P, Ballin M, Balloux F, Baral S, Bardosh K, et al.
J Clin Epidemiol
. 2024 Jun;
173:111428.
PMID: 38897481
Consensus statements can be very influential in medicine and public health. Some of these statements use systematic evidence synthesis but others fail on this front. Many consensus statements use panels...
8.
Harris A, Wang T, Heng Y, Baker G, Le P, Wang J, et al.
Breast Cancer Res
. 2024 Jun;
26(1):102.
PMID: 38886818
Background: Early menarche is an established risk factor for breast cancer but its molecular contribution to tumor biology and prognosis remains unclear. Methods: We profiled transcriptome-wide gene expression in breast...
9.
Brufsky A, Maculaitis M, Kopenhafer L, Olsen P, Kurosky S, Arruda L, et al.
Future Oncol
. 2024 Jun;
20(29):2165-2177.
PMID: 38861295
: Assess factors associated with first-line (1L) treatment for HR+/HER2- metastatic breast cancer.: A cross-sectional survey of 250 US oncologists was conducted. Correlations were calculated between treatment class and demographics,...
10.
Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman R, et al.
Future Oncol
. 2024 Mar;
20(19):1309-1317.
PMID: 38536033
What Is This Summary About?: This summary describes an article published in the medical journal in September 2023. The article reports results from a study that looked at breast cancer...